Abstract
This Cross-sectional observational study was conducted to determine the clinical profile of drug-resistant tuberculosis in children. Patients were classified as monoresistant TB, polyresistant TB, multidrug resistant (MDR)-TB and extensively drug resistant (XDR — TB). We coined a term called as Partial XDR-TB when isolates of Mycobacterium tuberculosis were confirmed to be resistant in vitro to be MDR along with either a fluoroquinolone or an aminoglycoside resistance (apart from streptomycin). Of 500 children analysed, 34 (6.8%) had drug resistant TB. Mean age of presentation was 6.8±3.2 years (Male: Female ratio 13:21). 18 (52.9%) children had been treated for tuberculosis in the past (1 defaulted), 7 patients had been in contact with an adult suffering from drug resistant TB and 3 patients (10.3%) were HIV co-infected. Fourteen children (41.2 %) had MDR TB, 11 (32.4 %) had Partial XDR, 1 each (2.9 %) had polyresistant TB and XDR TB. Clinical features of DR-TB are similar in all age groups. Past history of TB with treatment with antitubercular agents, and contact with adults suffering with drug-resistant TB are important risk factors in development of drug-resistant -TB in children.
References
TB India 2010: RNTCP Status report. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi — 110001. Available from: http://www.tbcindia.org. Accessed on 24 November, 2010.
World Health Organization (WHO). Anti-Tuberculosis Drug Resistance in the World. Fourth ‘Global Report. Available at URL: http://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf. Accessed on 31 December, 2011.
World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis — 2006. Available at URL: http://www.tbrieder.org/publications/books_english/who_treatment_mdr.pdf. Accessed on 31December, 2011.
Shah I, Rahangdale A. Partial extensively drug resistance (XDR) tuberculosis in children. Indian Pediatr. 2011; 48:977–978.
World Health Organization (WHO). Guidance on providerinitiated HIV testing and counselling in health facilities. Available at URL: http://www.who.int/hiv/pub/vct/pitc/en/index.html. Accessed on 16February, 2012
Schaaf HS. Drug-resistant tuberculosis in children. S Afr Med J. 2007;97:995–997.
Alrajhi AA, Abdulwahab S, Almodovar E, Al-Abdely HM. Risk factors for drug-resistant Mycobacterium tuberculosis in Saudi Arabia. Saudi Med J. 2002;23:305–310.
Gordin FM, Nelson ET, Matts JP, Cohn DL, Ernst J, Benator D, et al. The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. Am J Respir Crit Care Med. 1996;154:1478–1483.
The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 1996;45:1–18.
Sharma SK, Turaga KK, Balamurugan A, Saha PK, Pandey RM, Jain NK, et al. Clinical and genetic risk factors for the development of multi-drug resistant tuberculosis in non-HIV infected patients at a tertiary care center in India: a case-control study. Infect Genet Evol. 2003;3:183–188.
Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali RE, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001;5:887–893.
Snider DE Jr, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis. 1985;132:125–132.
Schaaf HS, Vermeulen HA, Gie RP, Beyers N, Donald PR. Evaluation of young children in household contact with adult multidrug resistant pulmonary tuberculosis cases. Pediatr Infect Dis J. 1999;18:494–500.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shah, I., Chilkar, S. Clinical profile of drug resistant tuberculosis in children. Indian Pediatr 49, 741–744 (2012). https://doi.org/10.1007/s13312-012-0158-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-012-0158-6